Guomei Xu1, Meng Xia2, Chenjie Jiang1, Ying Yu1, Guomi Wang1, Jiaojiao Yuan1, Xingwu Duan3. 1. Department of Dermatology, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China. 2. Key Laboratory of Ethnomedicine Ministry of Education, School of Pharmacy, Minzu University of China, Beijing, China. 3. Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. Electronic address: drruiming@163.com.
Abstract
PURPOSE: This network meta-analysis was aimed to enhance the corresponding evidence with respect to the efficacy and safety of biologic treatments. METHODS: PubMed and EMBASE database searches were conducted. Odds ratios were used to evaluate multi-aspect comparisons. SUCRA was used to analyze the ranking of treatments in each endpoint. Psoriasis Area and Severity Index 50%, 75%, 90%, 100%, PGA, dermatology quality of life index were considered as outcomes while adverse events and discontinuation were adopted to evaluate safety. RESULTS: For safety issues, briakinumab was associated with least headache and itolizumab had the lowest risk of infection. Ustekinumab performed best in discontinuation. SUCRA ranked briakinumab, brodalumab, Infliximab and ixekizumab as the favorable efficacy therapies, while briakinumab and brodalumab seemed to have mild side effects. No heterogeneity was observed between these comparisons. CONCLUSIONS: Briakinumab performed relatively stable under efficacy and safety outcome. Infliximab can be a good choice for its lower risk of infection. Brodalumab present very good potential in efficacy outcome like PASI and PGA. More clinical trials are required to supply more data about discontinuation of infliximab and infection of brodalumab and larger RCT for assessment of briakinumab.
PURPOSE: This network meta-analysis was aimed to enhance the corresponding evidence with respect to the efficacy and safety of biologic treatments. METHODS: PubMed and EMBASE database searches were conducted. Odds ratios were used to evaluate multi-aspect comparisons. SUCRA was used to analyze the ranking of treatments in each endpoint. Psoriasis Area and Severity Index 50%, 75%, 90%, 100%, PGA, dermatology quality of life index were considered as outcomes while adverse events and discontinuation were adopted to evaluate safety. RESULTS: For safety issues, briakinumab was associated with least headache and itolizumab had the lowest risk of infection. Ustekinumab performed best in discontinuation. SUCRA ranked briakinumab, brodalumab, Infliximab and ixekizumab as the favorable efficacy therapies, while briakinumab and brodalumab seemed to have mild side effects. No heterogeneity was observed between these comparisons. CONCLUSIONS:Briakinumab performed relatively stable under efficacy and safety outcome. Infliximab can be a good choice for its lower risk of infection. Brodalumab present very good potential in efficacy outcome like PASI and PGA. More clinical trials are required to supply more data about discontinuation of infliximab and infection of brodalumab and larger RCT for assessment of briakinumab.
Authors: Emily Wright; Najeeda Yasmeen; Kinga Malottki; Laura M Sawyer; Emma Borg; Carsten Schwenke; Richard B Warren Journal: Dermatol Ther (Heidelb) Date: 2020-12-22
Authors: April W Armstrong; Ahmed M Soliman; Keith A Betts; Yan Wang; Yawen Gao; Vassilis Stakias; Luis Puig Journal: Dermatol Ther (Heidelb) Date: 2021-12-04